JP2024535913A - Ｋｒａｓ変異を有するがん患者の治療 - Google Patents

Ｋｒａｓ変異を有するがん患者の治療 Download PDF

Info

Publication number
JP2024535913A
JP2024535913A JP2024518869A JP2024518869A JP2024535913A JP 2024535913 A JP2024535913 A JP 2024535913A JP 2024518869 A JP2024518869 A JP 2024518869A JP 2024518869 A JP2024518869 A JP 2024518869A JP 2024535913 A JP2024535913 A JP 2024535913A
Authority
JP
Japan
Prior art keywords
group
cancer
kras
mutation
patent application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535913A5 (cg-RX-API-DMAC10.html
Inventor
ジャンーシン デュアン
アンロン リ
ファンイン モン
テンヤン チ
Original Assignee
アセンタウィッツ ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アセンタウィッツ ファーマシューティカルズ リミテッド filed Critical アセンタウィッツ ファーマシューティカルズ リミテッド
Publication of JP2024535913A publication Critical patent/JP2024535913A/ja
Publication of JP2024535913A5 publication Critical patent/JP2024535913A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024518869A 2021-09-26 2022-09-23 Ｋｒａｓ変異を有するがん患者の治療 Pending JP2024535913A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111130589.3 2021-09-26
CN202111130589.3A CN115869325A (zh) 2021-09-26 2021-09-26 化合物用于制备治疗kras突变癌症患者的药物的用途
PCT/CN2022/120817 WO2023046060A1 (zh) 2021-09-26 2022-09-23 治疗kras突变的癌症患者

Publications (2)

Publication Number Publication Date
JP2024535913A true JP2024535913A (ja) 2024-10-02
JP2024535913A5 JP2024535913A5 (cg-RX-API-DMAC10.html) 2025-09-26

Family

ID=85719305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518869A Pending JP2024535913A (ja) 2021-09-26 2022-09-23 Ｋｒａｓ変異を有するがん患者の治療

Country Status (6)

Country Link
US (1) US20250281514A1 (cg-RX-API-DMAC10.html)
EP (1) EP4406538A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024535913A (cg-RX-API-DMAC10.html)
KR (1) KR20240067907A (cg-RX-API-DMAC10.html)
CN (2) CN115869325A (cg-RX-API-DMAC10.html)
WO (1) WO2023046060A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118804755A (zh) * 2022-06-10 2024-10-18 深圳艾欣达伟医药科技有限公司 Akr1c3酶激活前药治疗癌症患者的方法
KR20260020475A (ko) 2023-06-06 2026-02-11 아센타위츠 파마슈티컬즈 리미티드 Akr1c3 효소 발현 수준과 kras 돌연변이의 상관관계 및 의학적 용도
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
WO2025140580A1 (zh) * 2023-12-28 2025-07-03 深圳艾欣达伟医药科技有限公司 化合物晶型
WO2026130539A1 (zh) * 2024-12-20 2026-06-25 深圳艾欣达伟医药科技有限公司 Akr1c3酶活化的化合物与免疫检查点抑制剂联用治疗癌症、肿瘤患者的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145092A1 (en) * 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
WO2019190331A1 (en) * 2018-03-29 2019-10-03 Achilles Medical Limited Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders
WO2020228685A1 (zh) * 2019-05-13 2020-11-19 深圳艾欣达伟医药科技有限公司 含氟化合物及抗癌医药用途
WO2021068952A1 (zh) * 2019-10-12 2021-04-15 南京明德新药研发有限公司 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015053413A1 (ja) * 2013-10-11 2015-04-16 千葉県 ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤
WO2016161342A2 (en) 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
KR101985778B1 (ko) 2015-11-16 2019-06-04 아센타위츠 파마슈티컬즈 리미티드 (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조
CN110139741A (zh) 2017-07-26 2019-08-16 北京阿迈特医疗器械有限公司 3d打印机及其打印方法
TW201919644A (zh) 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
CN112220742A (zh) 2019-07-15 2021-01-15 深圳艾欣达伟医药科技有限公司 稳定的ast-3424注射液制剂及制备方法
WO2021043275A1 (zh) 2019-09-05 2021-03-11 深圳艾欣达伟医药科技有限公司 注射液的包装瓶及包装套件、灌注加塞压盖装置和方法
CN118804755A (zh) * 2022-06-10 2024-10-18 深圳艾欣达伟医药科技有限公司 Akr1c3酶激活前药治疗癌症患者的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145092A1 (en) * 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
WO2019190331A1 (en) * 2018-03-29 2019-10-03 Achilles Medical Limited Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders
WO2020228685A1 (zh) * 2019-05-13 2020-11-19 深圳艾欣达伟医药科技有限公司 含氟化合物及抗癌医药用途
WO2021068952A1 (zh) * 2019-10-12 2021-04-15 南京明德新药研发有限公司 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF CANCER RESEARCH, vol. 11, no. 7, JPN6026017248, July 2021 (2021-07-01), pages 3645 - 3659, ISSN: 0005856664 *
MOLECULAR CANCER THERAPEUTICS, vol. 19, no. 10, JPN6026017249, 2020, pages 2139 - 2145, ISSN: 0005856665 *

Also Published As

Publication number Publication date
WO2023046060A9 (zh) 2023-08-31
EP4406538A1 (en) 2024-07-31
US20250281514A1 (en) 2025-09-11
EP4406538A4 (en) 2025-10-15
CN115869325A (zh) 2023-03-31
WO2023046060A8 (zh) 2023-11-09
WO2023046060A1 (zh) 2023-03-30
CN117956998A (zh) 2024-04-30
KR20240067907A (ko) 2024-05-17

Similar Documents

Publication Publication Date Title
EP4406538A1 (en) Treatment of cancer patients having kras mutations
JP6787792B2 (ja) がんの処置のための併用治療
RU2316326C2 (ru) Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины
KR102539920B1 (ko) 종양-치료용 약제학적 조성물
ES2684120T3 (es) Combinación de un inhibidor de IAP y un taxano
AU2018341454A1 (en) Compositions and methods for treating cancer
TWI685341B (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
ES3049047T3 (en) Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma
IL293208A (en) Combination therapy involving diaryl macrocyclic compounds
WO2023035223A1 (zh) 药物组合物及其用途
CN118829436A (zh) 治疗brca突变癌症患者的方法
ES2685974T3 (es) Derivados de cefalosporina para tratar el cáncer
CN113543784A (zh) 用于治疗或预防癌症的喹啉衍生物
JP7479292B2 (ja) 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物
KR20240041917A (ko) 암의 치료 및/또는 예방을 위한 의약품
WO2025082484A1 (zh) 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
CN118846070A (zh) 一种用于治疗kras突变肿瘤的药物组合物及应用
CN111514298B (zh) 质子泵抑制剂与pd-1轴结合拮抗剂的组合及其用途
CA3082839A1 (en) Methods of inhibiting tumor metastasis
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP2025143272A (ja) がんを処置する方法及び使用
HK40122790A (en) Methods and uses for treating cancer
EP4706657A1 (en) Combination therapy of pexidartinib and nintedanib for prevention or treatment of pulmonary fibrosis
WO2025188239A1 (en) Pan-tead inhibitors and methods thereof
TW202228674A (zh) 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260512